423 related articles for article (PubMed ID: 30387134)
1. Toll-like receptor 3 agonist poly I:C reinforces the potency of cytotoxic chemotherapy via the TLR3-UNC93B1-IFN-β signaling axis in paclitaxel-resistant colon cancer.
Zhao J; Xue Y; Pan Y; Yao A; Wang G; Li D; Wang T; Zhao S; Hou Y
J Cell Physiol; 2019 May; 234(5):7051-7061. PubMed ID: 30387134
[TBL] [Abstract][Full Text] [Related]
2. Poly I:C enhances cycloheximide-induced apoptosis of tumor cells through TLR3 pathway.
Jiang Q; Wei H; Tian Z
BMC Cancer; 2008 Jan; 8():12. PubMed ID: 18199340
[TBL] [Abstract][Full Text] [Related]
3. Synergy between RA and TLR3 promotes type I IFN-dependent apoptosis through upregulation of TRAIL pathway in breast cancer cells.
Bernardo AR; Cosgaya JM; Aranda A; Jiménez-Lara AM
Cell Death Dis; 2013 Jan; 4(1):e479. PubMed ID: 23370279
[TBL] [Abstract][Full Text] [Related]
4. Surface Toll-like receptor 3 expression in metastatic intestinal epithelial cells induces inflammatory cytokine production and promotes invasiveness.
Bugge M; Bergstrom B; Eide OK; Solli H; Kjønstad IF; Stenvik J; Espevik T; Nilsen NJ
J Biol Chem; 2017 Sep; 292(37):15408-15425. PubMed ID: 28717003
[TBL] [Abstract][Full Text] [Related]
5. TLR3 induction by anticancer drugs potentiates poly I:C-induced tumor cell apoptosis.
Taura M; Fukuda R; Suico MA; Eguma A; Koga T; Shuto T; Sato T; Morino-Koga S; Kai H
Cancer Sci; 2010 Jul; 101(7):1610-7. PubMed ID: 20367642
[TBL] [Abstract][Full Text] [Related]
6. Synergistic Inhibition of Drug-Resistant Colon Cancer Growth with PI3K/mTOR Dual Inhibitor BEZ235 and Nano-Emulsioned Paclitaxel via Reducing Multidrug Resistance and Promoting Apoptosis.
Hu Y; Zhang K; Zhu X; Zheng X; Wang C; Niu X; Jiang T; Ji X; Zhao W; Pang L; Qi Y; Li F; Li L; Xu Z; Gu W; Zou H
Int J Nanomedicine; 2021; 16():2173-2186. PubMed ID: 33758505
[TBL] [Abstract][Full Text] [Related]
7. Dual topology of functional Toll-like receptor 3 expression in human hepatocellular carcinoma: differential signaling mechanisms of TLR3-induced NF-kappaB activation and apoptosis.
Yoneda K; Sugimoto K; Shiraki K; Tanaka J; Beppu T; Fuke H; Yamamoto N; Masuya M; Horie R; Uchida K; Takei Y
Int J Oncol; 2008 Nov; 33(5):929-36. PubMed ID: 18949355
[TBL] [Abstract][Full Text] [Related]
8. Toll-like receptor 3 agonist poly(I:C)-induced antiviral response in human corneal epithelial cells.
Kumar A; Zhang J; Yu FS
Immunology; 2006 Jan; 117(1):11-21. PubMed ID: 16423036
[TBL] [Abstract][Full Text] [Related]
9. In Vivo Visualizing the IFN-β Response Required for Tumor Growth Control in a Therapeutic Model of Polyadenylic-Polyuridylic Acid Administration.
Nocera DA; Roselli E; Araya P; Nuñez NG; Lienenklaus S; Jablonska J; Weiss S; Gatti G; Brinkmann MM; Kröger A; Morón G; Maccioni M
J Immunol; 2016 Mar; 196(6):2860-9. PubMed ID: 26880763
[TBL] [Abstract][Full Text] [Related]
10. Temporally designed treatment of melanoma cells by ATRA and polyI: C results in enhanced chemokine and IFNβ secretion controlled differently by TLR3 and MDA5.
Szabo A; Osman RM; Bacskai I; Kumar BV; Agod Z; Lanyi A; Gogolak P; Rajnavolgyi E
Melanoma Res; 2012 Oct; 22(5):351-61. PubMed ID: 22797253
[TBL] [Abstract][Full Text] [Related]
11. Toll-like receptor 3 (TLR3) activation induces microRNA-dependent reexpression of functional RARβ and tumor regression.
Galli R; Paone A; Fabbri M; Zanesi N; Calore F; Cascione L; Acunzo M; Stoppacciaro A; Tubaro A; Lovat F; Gasparini P; Fadda P; Alder H; Volinia S; Filippini A; Ziparo E; Riccioli A; Croce CM
Proc Natl Acad Sci U S A; 2013 Jun; 110(24):9812-7. PubMed ID: 23716670
[TBL] [Abstract][Full Text] [Related]
12. [Effects of Poly I:C in inducing growth inhibition and apoptosis of human hepatocellular carcinoma cells].
Shen P; Jiang TW; Lu HQ; Zhang LZ; Han HX; Luo RC
Nan Fang Yi Ke Da Xue Xue Bao; 2009 Mar; 29(3):525-7. PubMed ID: 19304544
[TBL] [Abstract][Full Text] [Related]
13. TLR3-mediated IFN-β gene induction is negatively regulated by the TLR adaptor MyD88 adaptor-like.
Siednienko J; Halle A; Nagpal K; Golenbock DT; Miggin SM
Eur J Immunol; 2010 Nov; 40(11):3150-60. PubMed ID: 20957750
[TBL] [Abstract][Full Text] [Related]
14. IL-27 enhances the expression of TRAIL and TLR3 in human melanomas and inhibits their tumor growth in cooperation with a TLR3 agonist poly(I:C) partly in a TRAIL-dependent manner.
Chiba Y; Mizoguchi I; Mitobe K; Higuchi K; Nagai H; Nishigori C; Mizuguchi J; Yoshimoto T
PLoS One; 2013; 8(10):e76159. PubMed ID: 24155891
[TBL] [Abstract][Full Text] [Related]
15. Toll-like receptor 3 activation in retinal pigment epithelium cells - Mitogen-activated protein kinase pathways of cell death and vascular endothelial growth factor secretion.
Klettner A; Koinzer S; Meyer T; Roider J
Acta Ophthalmol; 2013 May; 91(3):e211-8. PubMed ID: 23387336
[TBL] [Abstract][Full Text] [Related]
16. Toll-like receptor 3 ligand-induced antiviral response in mouse osteoblastic cells.
Nakamura K; Deyama Y; Yoshimura Y; Suzuki K; Morita M
Int J Mol Med; 2007 May; 19(5):771-5. PubMed ID: 17390082
[TBL] [Abstract][Full Text] [Related]
17. Nanoparticle-mediated drug delivery to tumor neovasculature to combat P-gp expressing multidrug resistant cancer.
Bai F; Wang C; Lu Q; Zhao M; Ban FQ; Yu DH; Guan YY; Luan X; Liu YR; Chen HZ; Fang C
Biomaterials; 2013 Aug; 34(26):6163-74. PubMed ID: 23706689
[TBL] [Abstract][Full Text] [Related]
18. Targeted inhibition of phosphatidyl inositol-3-kinase p110β, but not p110α, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers.
Jeong JY; Kim KS; Moon JS; Song JA; Choi SH; Kim KI; Kim TH; An HJ
Apoptosis; 2013 Apr; 18(4):509-20. PubMed ID: 23371322
[TBL] [Abstract][Full Text] [Related]
19. Activation of Toll-like receptor 3 induces apoptosis of oral squamous carcinoma cells in vitro and in vivo.
Luo Q; Hu S; Yan M; Sun Z; Chen W; Chen F
Int J Biochem Cell Biol; 2012 Aug; 44(8):1266-75. PubMed ID: 22568929
[TBL] [Abstract][Full Text] [Related]
20. The expression and function of Toll-like receptors 3 and 9 in human colon carcinoma.
Nojiri K; Sugimoto K; Shiraki K; Tameda M; Inagaki Y; Kusagawa S; Ogura S; Tanaka J; Yoneda M; Yamamoto N; Okano H; Takei Y; Ito M; Kasai C; Inoue H; Takase K
Oncol Rep; 2013 May; 29(5):1737-43. PubMed ID: 23467704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
